By Marie Rosenthal
In a 20-0 vote with one abstention, the FDA vaccine advisory committee said the benefits of Moderna’s messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273, outweighed the risks for people aged 18 years and older, which is essentially a recommendation for the FDA’s granting an emergency use authorization (EUA). The FDA is expected to act quickly on the recommendation.
The vote and discussion were very different from the ones last week for the Pfizer/BioNTech